BOLTON SECURITIES CORPORATION’s Atossa Therapeutics ATOS Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$505	Buy	+50	New	+$607	﹤0.01%	1813

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's ATOS Position: Q1 2025 in Review

BOLTON SECURITIES CORPORATION opened a new position in Atossa Therapeutics (ATOS) in Q1 2025: 50 shares worth $505. The stake represents ﹤0.01% of the portfolio and ranks #1813 among its holdings.

84 funds tracked by Wall St. Rank hold ATOS as of Q1 2025.

BOLTON SECURITIES CORPORATION held 50 shares of Atossa Therapeutics worth $505 as of Q1 2025.
Atossa Therapeutics was a new BOLTON SECURITIES CORPORATION position in Q1 2025.
Atossa Therapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2025, its #1813 holding.
84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2025.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2025, filed 12 Nov 2026.